Editorial: Blank-check stem cells - Governor missed chance with state loan
By Sacramento Bee,
Sacramento Bee
| 07. 24. 2006
Embryonic stem cell research would seem to be an all-or-nothing proposition. Either you oppose use of embryos for medical science, supporting President Bush in his callous veto of expanded federal funding for such research, or you rally behind unfettered expenditures for regenerative medicine, with little governmental oversight over how public monies are allocated.
Actually, there is a third wave of opinion on stem cells, but you won't hear it from many politicians in this election season. The third wave supports increased spending for embryonic stem cell science, but wants safeguards to ensure that researchers stay within clear ethical lines. It wants transparency in decision-making and accountability to prevent money from being channeled inappropriately to favored researchers and biotech companies.
Last week, Gov. Arnold Schwarzenegger missed an opportunity to ally himself with this third wave. A day after Bush cast his first veto to reject a stem cell bill, Schwarzenegger announced a $150 million bridge loan to California's beleaguered stem cell research institute. This agency has been prevented from dispensing $3 billion in state funds -- authorized by voters in 2004...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...